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VORICONAZOLE COMPARED WITH LIPOSOMAL AMPHOTERICIN B 
FOR EMPIRICAL ANTIFUNGAL THERAPY IN PATIENTS WITH NEUTROPENIA 
AND PERSISTENT FEVER
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BSTRACT
 
Background
 
Patients with neutropenia and per-
sistent fever are often treated empirically with am-
photericin B or liposomal amphotericin B to prevent
invasive fungal infections. Antifungal triazoles offer
a potentially safer and effective alternative.
 
Methods
 
In a randomized, international, multi-
center trial, we compared voriconazole, a new sec-
ond-generation triazole, with liposomal amphoteri-
cin B for empirical antifungal therapy.
 
Results
 
A total of 837 patients (415 assigned to
voriconazole and 422 to liposomal amphotericin B)
were evaluated for success of treatment. The overall
success rates were 26.0 percent with voriconazole
and 30.6 percent with liposomal amphotericin B (95
percent confidence interval for the difference, ¡10.6
to 1.6 percentage points); these rates were indepen-
dent of the administration of antifungal prophylaxis
or the use of colony-stimulating factors. There were
fewer documented breakthrough fungal infections in
patients treated with voriconazole than in those
treated with liposomal amphotericin B (8 [1.9 per-
cent] vs. 21 [5.0 percent], P=0.02). The voriconazole
group had fewer cases of severe infusion-related re-
actions (P<0.01) and of nephrotoxicity (P<0.001).
The incidence of hepatotoxicity was similar in the
two groups. Patients receiving voriconazole had
more episodes of transient visual changes than
those receiving liposomal amphotericin B (22 per-
cent vs. 1 percent, P<0.001) and more hallucinations
(4.3 percent vs. 0.5 percent, P<0.001). Parenteral vor-
iconazole was changed to the oral formulation in 22
percent of the voriconazole group, with a reduction
in the mean duration of hospitalization by one day in
all patients (P=0.17) but by two days in patients at
high risk (P=0.03).
 
Conclusions
 
Voriconazole is a suitable alternative
to amphotericin B preparations for empirical antifun-
gal therapy in patients with neutropenia and persist-
ent fever. (N Engl J Med 2002;346:225-34.)
 
Copyright © 2002 Massachusetts Medical Society.
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NVASIVE fungal infections are important caus-
es of morbidity and mortality among patients
receiving cancer chemotherapy or undergoing
bone marrow or stem-cell transplantation.
 
1-3
 
Over the past two decades, empirical antifungal ther-
apy with conventional amphotericin B or liposomal
amphotericin B has become the standard of care in
reducing invasive fungal infections in patients with
neutropenia and persistent fever.
 
4-9
 
 Amphotericin B,
however, is associated with significant dose-limiting
nephrotoxicity and infusion-related reactions. Lipo-
somal amphotericin B is equivalent to conventional
amphotericin B for use as empirical antifungal ther-
apy and significantly reduces proven invasive fungal
infections, nephrotoxicity, and infusion-related reac-
tions.
 
10,11
 
 The high acquisition cost of liposomal am-
photericin B, however, has limited the use of this less
toxic formulation of amphotericin B. Moreover,
I
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breakthrough fungal infections, infusion-related re-
actions, and nephrotoxicity still occur in patients re-
ceiving liposomal amphotericin B.
Antifungal triazoles are promising agents for em-
pirical antifungal therapy.
 
12,13
 
 Fluconazole has been
studied for this indication, but its use is limited be-
cause it has a narrow antifungal spectrum restricted
to yeasts.
 
14-16
 
 Itraconazole also has been investigat-
ed.
 
17
 
 However, its oral administration is limited be-
cause of the erratic bioavailability of the capsule form
and the adverse gastrointestinal effects of the oral so-
lution. Moreover, there has been limited experience
with the new parenteral formulation. The new gen-
eration of antifungal triazoles that includes voricon-
azole has a broad in vitro spectrum, potent in vivo
activity, a favorable safety profile, and excellent bio-
availability.
 
18-20
 
 We reasoned that voriconazole, a sec-
ond-generation triazole, might be as effective as
conventional or liposomal amphotericin B for em-
pirical antifungal therapy, but less toxic.
 
METHODS
 
Study Design
 
The study was an open-label, prospective, randomized, multi-
center, international comparative trial of voriconazole and liposo-
mal amphotericin B, conducted between March 1998 and Sep-
tember 1999. The study was reviewed by an institutional review
board or ethics committee at each of the 73 participating centers.
Written informed consent was obtained from each patient or his
or her legal guardian before enrollment in the study. The data
safety and monitoring board of the National Institute of Allergy
and Infectious Diseases Mycoses Study Group was convened to
review data in order to monitor patient safety. A data-review com-
mittee composed of a panel of blinded investigators with expertise
in the study and treatment of fungal infections reviewed and clas-
sified all documented (proven and probable) fungal infections, us-
ing protocol-defined criteria.
 
21
 
Enrollment, Stratification, and Randomization
 
Eligible patients were at least 12 years of age; had received che-
motherapy for leukemia, lymphoma, or other cancers or had un-
dergone transplantation of hematopoietic stem cells; and had re-
ceived more than 96 hours of systemic antibacterial therapy while
continuing to have fever (oral temperature above 38°C within 24
hours before randomization) and neutropenia (an absolute neu-
trophil count below 500 cells per cubic millimeter for 96 hours
and below 250 cells per cubic millimeter within 24 hours before
randomization). Patients were not eligible if they had a docu-
mented invasive fungal infection at the time of randomization or
serum levels of aspartate aminotransferase, alanine aminotransferase,
alkaline phosphatase, or bilirubin that were more than five times the
upper limit of normal.
Patients at each center were stratified according to their degree
of risk for fungal infection and the use or nonuse of systemic anti-
fungal prophylaxis. Patients were randomly assigned to receive either
voriconazole or liposomal amphotericin B, in a 1:1 ratio, according
to a computer-generated randomization system with a two-per-
block design. Patients at high risk were defined as those who had
received allogeneic hematopoietic stem-cell transplants or who
were receiving chemotherapy for relapsed leukemia. Other patients
were classified as being at moderate risk.
 
Administration of Study Drugs
 
Voriconazole was administered intravenously on day 1 as a load-
ing dose of 6 mg per kilogram of body weight every 12 hours for
two doses and then continued at a maintenance dose of 3 mg per
kilogram intravenously every 12 hours (or 200 mg orally every 12
hours, after at least three days of intravenous therapy). Liposomal
amphotericin B was initiated and continued at 3 mg per kilogram
intravenously per day. After protocol-defined guidelines for evi-
dence of fungal infection had been met, investigators were permit-
ted to increase the dose of voriconazole to 4 mg per kilogram in-
travenously every 12 hours or 300 mg orally every 12 hours and
the dose of liposomal amphotericin B to 6 mg per kilogram in-
travenously per day. If toxic effects occurred, lowering of the dose
of liposomal amphotericin B to 1.5 mg per kilogram per day was
permitted. No dose reduction was permitted for voriconazole un-
less there had been a prior dose escalation. On the basis of the
assessment of the primary physician, patients who were unable to
tolerate or did not respond to the study drug were removed from
the clinical trial. Patients continued therapy for up to 3 days after
neutrophil recovery (defined as an absolute neutrophil count of
at least 250 cells per cubic millimeter), or up to a maximum of 12
weeks in those with documented invasive fungal infections. All in-
fusion-related reactions were monitored prospectively with a previ-
ously validated bedside monitoring form.
 
Antifungal Activity and Pharmacokinetics of Voriconazole
 
Minimal inhibitory concentrations of voriconazole and ampho-
tericin B were determined in a central reference laboratory ac-
cording to the guidelines of the National Committee for Clinical
Laboratory Standards
 
22,23
 
 for yeasts and filamentous fungi isolated
from patients with documented invasive fungal infections. Plasma
voriconazole levels were determined in each patient by high-per-
formance liquid chromatography of blood collected twice weekly,
according to a minimal sampling strategy.
 
24
 
Composite Outcome Score
 
Treatment was considered successful if the patient did not have a
breakthrough fungal infection, survived for seven days beyond the
end of therapy, did not discontinue therapy prematurely, had reso-
lution of fever during the period of neutropenia, and was success-
fully treated for any base-line fungal infection. Encompassing at least
one end point from each earlier trial,
 
6-8,11,14,15
 
 this composite scoring
system has been used and validated in other studies of empirical an-
tifungal therapy.
 
10,16,17
 
 Secondary analyses of individual composite
end points were exploratory assessments and were not intended to
be a primary determination of outcome superiority.
 
Statistical Analysis
 
Noninferiority was predefined as a difference in success rates be-
tween voriconazole and liposomal amphotericin B of no more than
10 percentage points. On the assumption of a success rate of 50 per-
cent, a sample of 393 patients who could be evaluated in each treat-
ment group (a total of 786) was required to demonstrate noninfe-
riority at the two-sided significance level of 5 percent with a power
of 80 percent.
 
25
 
 Thus, a 95 percent confidence interval for the dif-
ference in response rates within 10 percentage points in either di-
rection was required for voriconazole to be considered not inferior
to liposomal amphotericin B. On the assumption of a 10 percent
loss of patients from the modified intention-to-treat population, a
total sample size of 866 needed to be enrolled. The population for
the primary analysis (the modified intention-to-treat population)
was defined as the patients who were randomly assigned to treat-
ment, who received one or more doses of study drug, and for whom
the data were sufficient to permit evaluation. The sample was also
sufficiently large that the study was prospectively projected to assess
the effect of the study drug on the prevention of invasive fungal in-
fections, given the assumption of a 6 percent frequency of infection,
a reduction to 2 percent, and a two-tailed alpha level of 0.05.
The New England Journal of Medicine 
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Outcome indicators were analyzed on the basis of the confi-
dence interval around the difference in success rates and by the
Cochran–Mantel–Haenszel chi-square test in the modified inten-
tion-to-treat population. A 95 percent two-sided confidence in-
terval was constructed around the difference in success rates be-
tween the two treatment groups. The rates of adverse events and
other safety-related variables were tabulated according to treatment
group, and selected variables were analyzed by the chi-square test
or Fisher’s exact test. A Kaplan–Meier analysis of time to deferves-
cence was plotted.
The patients’ utilization of health care resources was prospective-
ly studied. We hypothesized that the availability of the oral formu-
lation of voriconazole would lead to earlier hospital discharge.
The total number of inpatient days was analyzed by the Wilcoxon
rank-sum test (two-sided).
 
RESULTS
 
Patient Population
 
A total of 849 patients received at least one dose
of study drug. Among the 837 patients in the mod-
ified intention-to-treat population, 415 received vor-
iconazole and 422 received liposomal amphotericin
B. The study groups were similar with regard to age,
sex, race, underlying primary neoplastic disease, and
risk of fungal infection (Table 1). Antibacterial thera-
py, including use of aminoglycosides, use of antiviral
agents, and modifications of initial antibiotic therapy,
was also similar in the two treatment groups. Thirteen
patients in the voriconazole group and six patients
in the liposomal amphotericin B group had base-line
fungal infections documented within the first 24 hours
after entry to the study (Table 1).
 
Efficacy
 
The overall success rate according to the compos-
ite score and the response according to each of its
five components are shown in Table 2. The overall
success rate among patients in the modified inten-
tion-to-treat population was 26.0 percent for those
receiving voriconazole and 30.6 percent for those
receiving liposomal amphotericin B (95 percent con-
fidence interval for the difference, ¡10.6 to 1.6 per-
centage points). This 95 percent confidence interval
falls just outside the predefined lower limit of ¡10
percentage points. Among the five components in the
composite score, the only significant difference was
found in the frequency of breakthrough fungal in-
fections.
Documented breakthrough fungal infections oc-
curred in 8 patients receiving voriconazole and 21
patients receiving liposomal amphotericin B (P=
0.02) (Table 3). There were fewer cases of document-
ed breakthrough invasive aspergillosis, candidemia, and
dematiaceous mold infections among patients re-
ceiving voriconazole, and fewer cases of zygomycosis
among patients receiving liposomal amphotericin B.
We further evaluated the effect of breakthrough fungal
infections by examining 30-day mortality. Among
the 29 patients with breakthrough fungal infections,
14 (48.3 percent) died from invasive mycosis; in com-
parison, the overall mortality in this study was 12.9
percent (108 of 837, P<0.001).
The reduction in invasive fungal infections was par-
ticularly apparent in the stratified cohort of patients
at high risk (those with allogeneic transplants or re-
lapsed leukemia) (Table 4). Among these patients,
those receiving voriconazole had fewer documented
breakthrough fungal infections than those receiving
liposomal amphotericin B (2 of 143 [1.4 percent] vs.
13 of 141 [9.2 percent], P=0.003). The protective
effect of voriconazole was also evident in the high-
risk population among patients who were receiving
systemic antifungal prophylaxis: 1.2 percent of these
patients had invasive fungal infections, as compared
with 9.1 percent in the liposomal amphotericin B
group (P=0.02).
The most common documented base-line fungal
infection was candidemia, followed by pulmonary
aspergillosis, disseminated zygomycosis, and tricho-
derma fungemia. Similar proportions of base-line
fungal infections responded to voriconazole and lip-
osomal amphotericin B (6 of 13 [46.2 percent]
and 4 of 6 [66.7 percent], respectively; P=0.63)
(Table 2).
There was no significant difference in overall mor-
tality between the voriconazole and liposomal am-
photericin B groups. However, among the patients
who died, more patients in the voriconazole group
than in the liposomal amphotericin B group died of
progressive underlying neoplastic disease (13 vs. 5,
P=0.06). There were also more deaths from bacterial
pneumonia or sepsis among the patients with pro-
gressive cancer.
There was a trend toward more frequent prema-
ture discontinuation of the study drug in the vori-
conazole group than in the liposomal amphotericin
B group. The number of patients discontinuing the
drug because of toxic effects was similar in the two
groups (19 in the voriconazole group and 23 in the
liposomal amphotericin B group). However, there
were more discontinuations due to lack of efficacy in
patients who received voriconazole (22 vs. 5, P=
0.001), with persistent fever being the most common
reason for withdrawal (14 vs. 2, P=0.002). None of
these fevers were due to documented breakthrough
fungal infections. Despite these withdrawals because
of fever, the overall frequency of resolution of fever
and the time to resolution of fever were virtually
identical in the two study groups according to Kap-
lan–Meier analysis (Fig. 1).
 
Effect of Risk Stratification on Outcome
 
Among patients at high risk, the overall success rate
was 32 percent for voriconazole and 30 percent for
The New England Journal of Medicine 
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*Because of rounding, not all percentages add to 100.
†Patients at high risk had undergone allogeneic hematopoietic transplantation or had relapsed leu-
kemia. Among patients with relapsed leukemia, 31 of 92 patients receiving voriconazole (34 percent)
and 27 of 84 patients receiving liposomal amphotericin B (32 percent) also underwent allogeneic
hematopoietic transplantation.
‡Antifungal prophylaxis was defined as treatment with systemically absorbed or parenterally admin-
istered antifungal agents for the prevention of invasive fungal infections before randomization.
§Cytokines were granulocyte colony-stimulating factor and granulocyte–macrophage colony-stim-
ulating factor.
¶Invasive fungal infections (as defined by modified criteria of the European Organization for Re-
search and Treatment of Cancer–Mycosis Study Group
 
21
 
) documented within 24 hours after study
entry are listed. One patient in the voriconazole group had disseminated zygomycosis, and one in the
amphotericin B group had trichoderma fungemia at base line. Among patients with base-line fungal
infections, 2 of 13 assigned to voriconazole (15 percent) received antifungal prophylaxis (fluconazole
in both cases), and 3 of 6 assigned to liposomal amphotericin B (50 percent) received antifungal
prophylaxis (fluconazole in 2 cases and low-dose deoxycholate amphotericin B in 1 case).
¿Ninety-two patients (22 percent) received the oral formulation of voriconazole.
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C
 
HARACTERISTIC
 
V
 
ORICONAZOLE
 
(N=415)
L
 
IPOSOMAL
 
 A
 
MPHOTERICIN
 
 B
(N=422)
 
Age — yr
Mean 46.3 45.0
Range 12–82 12–80
Age group — no. (%)
<18 yr 13 (3.1) 20 (4.7)
18–44 yr 161 (38.8) 177 (41.9)
45–64 yr 190 (45.8) 181 (42.9)
»65 yr 51 (12.3) 44 (10.4)
Sex — no. (%)
Male 233 (56.1) 216 (51.2)
Female 182 (43.9) 206 (48.8)
Race — no. (%)
White 325 (78.3) 333 (78.9)
Black 35 (8.4) 32 (7.6)
Other 55 (13.3) 57 (13.5)
Risk category — no. (%)†
High 143 (34.5) 141 (33.4)
Moderate 272 (65.5) 281 (66.6)
Antifungal prophylaxis — no. (%)‡ 222 (53.5) 250 (59.2)
Hematopoietic transplantation — no. (%) 198 (47.7) 217 (51.4)
Allogeneic 76 (18.3) 79 (18.7)
Autologous 122 (29.4) 139 (32.9)
Primary diagnosis — no. (%)
Newly diagnosed leukemia 130 (31.3) 130 (30.8)
Relapsed leukemia 92 (22.2) 84 (19.9)
Lymphoma 57 (13.7) 63 (14.9)
Multiple myeloma 22 (5.3) 24 (5.7)
Solid tumor 52 (12.5) 58 (13.7)
Other 62 (14.9) 63 (14.9)
Antibiotic treatment — no. (%)
Aminoglycosides 199 (48.0) 216 (51.2)
Antiviral agent 277 (66.7) 297 (70.4)
Modification of initial therapy 66 (15.9) 75 (17.8)
Cytokines — no. (%)§ 192 (46.3) 201 (47.6)
Duration of neutropenia — days
Before randomization
Median 7.7 7.6
Range 2.4–71 2.4–60
Total duration
Median 15.2 14.2
Range 3.3–119 4.2–75
Base-line fungal infections — no.¶ 13 6
Candida 10 3
Aspergillus 2 2
Other organisms 1 1
Duration of administration of study drug — days¿
Median 7 7
Range 1–113 1–81
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liposomal amphotericin B (95 percent confidence in-
terval for the difference, ¡9.0 to 12.4 percentage
points). By comparison, among patients at moderate
risk, the overall success rate was lower for voricona-
zole (23 percent) than for liposomal amphotericin B
(31 percent) (95 percent confidence interval for the
difference, ¡15.2 to ¡0.4 percentage points). This
difference in efficacy among patients at moderate
risk was due mainly to a disparity in mortality from
progressive cancer. Although these patients were at
lower risk for invasive fungal infections, they were
not at lower risk for death due to other causes, in-
cluding cancer.
 
Safety and Tolerability
 
Infusion-Related Reactions
 
Abnormal vision characterized by a transient alter-
ation in the perception of light was the most common
infusion-related toxic effect of voriconazole (Table
5). This effect was observed most frequently at the
time of the first infusion and disappeared during sub-
sequent infusions. Patients receiving liposomal am-
photericin B had more episodes of acute infusion-
related reactions than those receiving voriconazole.
 
Hepatotoxicity and Nephrotoxicity
 
There were no significant differences between the
study groups in hepatotoxicity, as measured by ele-
vations in serum aspartate aminotransferase, alanine
aminotransferase, and alkaline phosphatase levels (Ta-
ble 5). Serum bilirubin levels were more commonly
elevated in recipients of liposomal amphotericin B.
There was a greater frequency of azotemia among
patients receiving liposomal amphotericin B, as de-
fined by an elevation in the serum creatinine level to
more than 1.5 times the base-line value; however,
there was no significant difference in the frequency of
serum creatinine levels that were more than two
times the base-line value. There also was a greater
frequency of moderate hypokalemia (defined as a se-
rum potassium level «3.0 mmol per liter) and severe
hypokalemia («2.5 mmol per liter) in patients re-
ceiving liposomal amphotericin B.
 
Visual Hallucinations and Other Toxic Effects
 
Visual hallucinations were more frequent in pa-
tients receiving voriconazole than in those receiving
liposomal amphotericin B (18 [4.3 percent] vs. 2 [0.5
percent], P<0.001). In most cases these effects were
distinct from infusion-related altered perception of
light. There were no differences between the groups
in the frequency of treatment-related rash or cardiac-
associated adverse events.
 
Use of Health Care Resources
 
Ninety-two patients (22 percent) were able to re-
ceive the oral formulation of voriconazole. Patients
receiving voriconazole had a nonsignificant reduction
in the duration of hospitalization, with a median dif-
ference of one day (P=0.17). Patients at high risk
(those with allogeneic transplants or relapsed leuke-
mia) who received voriconazole had a significant re-
duction in the duration of hospitalization with a me-
dian difference of two days (P=0.03).
 
Antifungal Activity and Pharmacokinetics of Voriconazole
 
Mean plasma voriconazole levels between 2 and
4 μg per milliliter were sustained throughout the
 
*The causes of death for patients in the voriconazole and liposomal amphotericin B groups, respectively, as assessed by the principal in-
vestigators, were as follows: progression of cancer (13 and 5 patients), respiratory failure (4 and 3 patients), renal failure (2 patients and
1 patient), sepsis (15 and 9 patients), bacterial pneumonia (7 patients and 1 patient), hemorrhage (0 and 6 patients), disseminated fungal
infection (1 patient and 2 patients), ventricular fibrillation (1 patient and 0), and other causes (5 and 4 patients).
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ORICONAZOLE
 
(N=415)
L
 
IPOSOMAL
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MPHOTERICIN
 
 B
(N=422)
P
 
OINT
 
 E
 
STIMATE
 
 
 
FOR
THE
 
 PERCENT DIFFERENCE
(95% CONFIDENCE INTERVAL)
Overall response — no. (%) 108 (26.0) 129 (30.6) ¡4.5 (¡10.6 to 1.6)
No breakthrough fungal infections within 7 days 
of end of therapy — no. (%)
407 (98.1) 401 (95.0) +3.1 (0.6 to 5.5)
Survival 7 days after end of therapy — no. (%)* 382 (92.0) 397 (94.1) ¡2.0 (¡5.5 to 1.4)
No discontinuation due to toxicity or lack of efficacy
before recovery from neutropenia — no. (%)
374 (90.1) 394 (93.4) ¡3.2 (¡7.0 to 0.5)
Resolution of fever during neutropenia — no. (%) 135 (32.5) 154 (36.5) ¡4.0 (¡10.4 to 2.5)
Complete or partial response of patients with base-line fungal 
infections by end of treatment — no./total no. (%)
6/13 (46.2) 4/6 (66.7) ¡20.5 (¡67.0 to 25.9)
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12-hour dosing interval. Approximately 75 percent
of the plasma voriconazole levels were between 1 and
7 μg per milliliter during the dosing interval. Among
15 isolates of candida species recovered from 10 pa-
tients with fungemia, only 1 isolate (Candida gla-
brata) was associated with a minimal inhibitory con-
centration of voriconazole (4 μg per milliliter) that
exceeded plasma levels achieved by voriconazole at
the dosages used in this study. This isolate was also
resistant to other antifungal triazoles. Among five
isolates of aspergillus species, the minimal inhibitory
concentration of voriconazole was within achievable
levels.
DISCUSSION
In this randomized comparison of voriconazole
with liposomal amphotericin B for empirical antifun-
gal therapy in patients with neutropenia and persistent
fever, voriconazole did not fulfill the protocol-defined
criteria for noninferiority to liposomal amphotericin
B with respect to overall response to empirical ther-
apy, since the 95 percent confidence limit of ¡10.6
percentage points fell just outside the predefined low-
er bound of ¡10 percentage points. However, exam-
ination of the individual elements of the composite
score for success indicated that the two treatments
were similar and that voriconazole was superior in
reducing documented breakthrough fungal infec-
tions, infusion-related toxicity, and nephrotoxicity.
The activity of voriconazole in the prevention of
breakthrough fungal infections in this study is con-
sistent with its efficacy in a recently completed clin-
ical trial involving primary treatment of documented
invasive aspergillosis.26 These effects may be related
to the combination of its potent in vitro antifungal
activity (indicated by low minimal inhibitory con-
centrations against most yeasts and filamentous fungi)
*Breakthrough invasive fungal infections were defined according to
modified criteria of the European Organization for Research and Treat-
ment of Cancer–Mycosis Study Group.21
†The zygomycetes were one rhizopus species and one unidentified spe-
cies that was histologically documented to have characteristic features of
zygomycetes.
‡The dematiaceous molds were one alternaria species and one unidenti-
fied species that was histologically documented to have the pigmented cell
walls that are characteristic of these organisms.
§P=0.02 for the comparison with the voriconazole group.
TABLE 3. DOCUMENTED BREAKTHROUGH INVASIVE FUNGAL 
INFECTIONS.*
VARIABLE
VORICON-
AZOLE
LIPOSOMAL
AMPHOTERICIN B
Organism and site (no. of cases)
Aspergillus species
Lungs 4 9
Sinuses 0 2
Central nervous system or skin 0 1
Disseminated 0 1
Total 4 13
Candida species
Disseminated 1 0
Blood 1 6
Total 2 6
Zygomycetes†
Lung 1 0
Nasal passages 1 0
Total 2 0
Dematiaceous molds‡
Blood 0 1
Lungs 0 1
Total 0 2
Total breakthrough invasive fungal infections 8 21§
Demographic and clinical characteristics
Primary condition (no. of cases)
Acute leukemia 6 16
Multiple myeloma 1 0
Myelodysplasia 1 1
Lymphoma 0 4
Duration of neutropenia before infection 
(days)
Median 26 18
Range 12–106 6–63
Duration of administration of study drug 
before infection (days)
Median 13 6
Range 4–45 2–41
Systemic antifungal prophylaxis (no. of cases) 2 13
*Antifungal prophylaxis was defined as treatment with systemically ab-
sorbed or parenterally administered antifungal agents for the prevention of
invasive fungal infections before randomization.
†Patients at high risk had undergone allogeneic hematopoietic transplan-
tation or had relapsed leukemia.
‡P=0.003 for the comparison of voriconazole with amphotericin B.
§P not significant.
¶P=0.02 for the comparison of voriconazole with amphotericin B.
TABLE 4. DOCUMENTED BREAKTHROUGH FUNGAL INFECTIONS 
DURING EMPIRICAL ANTIFUNGAL THERAPY, 
ACCORDING TO RISK CATEGORY.
RISK GROUP
ANTIFUNGAL
PROPHYLAXIS*
NO
ANTIFUNGAL
PROPHYLAXIS TOTAL
no. of cases/total no. (%)
High risk†
Voriconazole 1/83  (1.2) 1/60  (1.7) 2/143 (1.4)‡
Liposomal ampho-
tericin B
9/99  (9.1) 4/42  (9.5) 13/141 (9.2)‡
Moderate risk
Voriconazole 1/139 (0.7) 5/133 (3.8) 6/272 (2.2)§
Liposomal ampho-
tericin B
4/151 (2.6) 4/130 (3.1) 8/281 (2.8)§
Total
Voriconazole 2/222 (0.9) 6/193 (3.1) 8/415 (1.9)¶
Liposomal ampho-
tericin B
13/250 (5.2) 8/172 (4.7) 21/422 (5.0)¶
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and its pharmacokinetic properties.12,13,26-28 The low
molecular weight of voriconazole (349.3) may permit
penetration into the endobronchial-lining fluid and
other mucosal surfaces.28 The fact that the plasma
pharmacokinetics in our study demonstrated circulat-
ing voriconazole levels well above the minimal inhib-
itory concentration for most fungal pathogens dur-
ing its 12-hour dosing interval may also contribute
to its clinical antifungal activity.
Empirical antifungal therapy with voriconazole
should be used in patients with persistent neutrope-
nia, who are at high risk for invasive antifungal in-
fections.29-32 In the prospectively defined high-risk
group in our study, the overall response rate among
patients who received voriconazole was similar to
the rate among those who received liposomal am-
photericin B, and the frequency of breakthrough
fungal infections was significantly reduced in the
voriconazole group.
The open-label design of this trial permitted us to
evaluate the effect of oral voriconazole on time of
discharge, but it may have created a bias in favor of
liposomal amphotericin B, with which there is ex-
tensive clinical experience. Significantly more patients
receiving voriconazole than those receiving liposom-
al amphotericin B were removed prematurely from
the study because of persistent fever in the absence
of evidence of fungal infection, despite similar frequen-
cies of fever in both groups. A similar pattern was seen
in a large, randomized, open-label study comparing
amphotericin B and fluconazole for candidemia, in
which patients receiving fluconazole were removed
from the study because of persistent fever, despite clin-
ical stability and repeatedly negative blood cultures.33
In this study, the infusion-related reactions to vor-
iconazole and liposomal amphotericin B were char-
acterized by prospective bedside monitoring of more
than 10,000 infusions. Although liposomal ampho-
tericin B is well known to have significantly lower in-
fusion-related toxicity than conventional amphotericin
B,10 severe acute reactions have been described.34-37
In our study, 65 percent of the instances of discon-
tinuation of liposomal amphotericin B were due to a
syndrome that included dyspnea, hypoxemia, urticar-
ia, and chest, abdominal, or flank pain. By compari-
son, the only significant infusion-related reaction to
voriconazole was transient photopsia, which was not
associated with discontinuation of therapy.
More patients receiving liposomal amphotericin B
had azotemia (defined as a serum creatinine level more
than 1.5 times the base-line level), hypokalemia, or
hypomagnesemia. However, there was no significant
difference between the groups in the proportion of
patients with serum creatinine levels of more than
Figure 1. Kaplan–Meier Estimates of the Time to Resolution of Fever in Patients with Neutropenia and Persistent Fever
Who Were Randomly Assigned to Receive Voriconazole or Liposomal Amphotericin B as Empirical Antifungal Therapy.
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*P values indicating significant differences are shown.
†A total of 10,398 infusions were prospectively monitored: 6053 in the voriconazole group and
4345 in the liposomal amphotericin B group.
‡Nephrotoxic drugs were aminoglycosides, cyclosporine, and foscarnet.
§To convert the values for magnesium to millimoles per liter, multiply by 0.5.
¶Figures are for patients with base-line values 2 to 5 times the upper limit of normal.
¿Figures are for patients with base-line values <2 times the upper limit of normal.
TABLE 5. INFUSION-RELATED REACTIONS AND LABORATORY ABNORMALITIES IN PATIENTS 
TREATED WITH VORICONAZOLE OR LIPOSOMAL AMPHOTERICIN B.
RESPONSE
VORICONAZOLE
(N=415)
LIPOSOMAL
AMPHOTERICIN B
(N=422)
P
VALUE*
no./total no. (%)
Infusion-related reactions†
Abnormal vision 91 (21.9) 3 (0.7) <0.001
Chest pain 1 (0.2) 17 (4.0) <0.001
Abdominal pain 1 (0.2) 12 (2.8) 0.002
Back pain 0 14 (3.3) <0.001
Flank pain 1 (0.2) 8 (1.9) 0.038
Dyspnea 3 (0.7) 37 (8.8) <0.001
Anaphylactoid reaction 0 7 (1.7) 0.02
Flushing 14 (3.4) 46 (10.9) <0.001
Sweating 3 (0.7) 9 (2.1)
Urticaria 1 (0.2) 3 (0.7)
Cyanosis 0 2 (0.5)
Chills 57 (13.7) 126 (29.9) <0.001
Cardiac arrest 1 (0.2) 0 
Nausea 39 (9.4) 53 (12.6)
Laboratory abnormalities
Serum creatinine during therapy
>1.5¬ base line 43 (10.4) 80 (19.0) <0.001
>2.0¬ base line 29 (7.0) 32 (7.6)
Nephrotoxicity with concomitant nephro-
toxic drugs‡
0 or 1 drug 42/372 (11.3) 37/381 (9.7)
»2 drugs 6/42  (14.3) 16/241 (39.0) 0.01
»3 drugs 2/4  (50.0) 3/5  (60.0)
Hypokalemia
Potassium «3.0 mmol/liter 68 (16.4) 131 (31.0) <0.001
Potassium «2.5 mmol/liter 10 (2.4) 21 (5.0) <0.05
Hypomagnesemia§
Magnesium «0.75 mg/dl 261 (62.9) 275 (65.2)
Magnesium «0.60 mg/dl 65 (15.7) 72 (17.1)
Serum alkaline phosphatase
>3¬ the base-line value¶ 0 2 (0.5)
>5¬ the base-line value¿ 12 (2.9) 18 (4.3)
Serum aspartate aminotransferase
>3¬ the base-line value¶ 0 0
>5¬ the base-line value¿ 37 (8.9) 27 (6.4)
Serum alanine aminotransferase
>3¬ the base-line value¶ 1 (0.2) 0 
>5¬ the base-line value¿ 29 (7.0) 34 (8.1)
Serum bilirubin during therapy
»1.5¬ base line 73 (17.6) 97 (23.0) 0.05
»3.0¬ base line 40 (9.6) 46 (10.9)
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two times base line, a result consistent with the sub-
stantially lower nephrotoxicity of liposomal ampho-
tericin B in comparison with that of conventional
amphotericin B. Voriconazole was not associated with
any increase in the frequency of hepatic or renal ab-
normalities. The low frequency of hepatotoxicity with
empirical therapy in our study may not pertain in
patients undergoing more prolonged treatment for
proven infection. In addition to its lower rates of
nephrotoxicity and hepatotoxicity, the reliable oral bio-
availability of voriconazole may make possible earlier
hospital discharge and substantial cost savings in se-
lected patients.
This study demonstrates that voriconazole, a sec-
ond-generation triazole, is an appropriate agent for
empirical antifungal therapy and that its use may re-
duce the frequency of proven breakthrough fungal
infections, preserve renal function, and reduce the
frequency of acute infusion-related toxic effects. For-
mulations of amphotericin B have been the standard
of empirical antifungal therapy for nearly 20 years.
As this study shows, a second-generation triazole can
be used in lieu of amphotericin B for early antifungal
therapy.
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